Vaccine plus microbicide effective in preventing vaginal SIV transmission in macaques.
Journal
Nature microbiology
ISSN: 2058-5276
Titre abrégé: Nat Microbiol
Pays: England
ID NLM: 101674869
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
02
08
2022
accepted:
02
03
2023
medline:
8
5
2023
pubmed:
7
4
2023
entrez:
6
4
2023
Statut:
ppublish
Résumé
The human immunodeficiency virus epidemic continues in sub-Saharan Africa, and particularly affects adolescent girls and women who have limited access to antiretroviral therapy. Here we report that the risk of vaginal simian immunodeficiency virus (SIV)
Identifiants
pubmed: 37024617
doi: 10.1038/s41564-023-01353-7
pii: 10.1038/s41564-023-01353-7
pmc: PMC10159859
doi:
Substances chimiques
SAIDS Vaccines
0
Vaccines
0
Anti-Infective Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
905-918Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
UNAIDS. FACT SHEET – WORLD AIDS DAY 2021 Vol. 2022 (UNAIDS, 2021).
Birdthistle, I. et al. Recent levels and trends in HIV incidence rates among adolescent girls and young women in ten high-prevalence African countries: a systematic review and meta-analysis. Lancet Glob. Health 7, e1521–e1540 (2019).
pubmed: 31607465
pmcid: 7025003
doi: 10.1016/S2214-109X(19)30410-3
Flynn, N. M. et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191, 654–665 (2005).
pubmed: 15688278
doi: 10.1086/428404
Pitisuttithum, P. et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661–1671 (2006).
pubmed: 17109337
doi: 10.1086/508748
Buchbinder, S. P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881–1893 (2008).
pubmed: 19012954
pmcid: 2721012
doi: 10.1016/S0140-6736(08)61591-3
Gray, G. E. et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect. Dis. 11, 507–515 (2011).
pubmed: 21570355
pmcid: 3417349
doi: 10.1016/S1473-3099(11)70098-6
Gray, G. E. et al. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect. Dis. 14, 388–396 (2014).
pubmed: 24560541
pmcid: 4174314
doi: 10.1016/S1473-3099(14)70020-9
Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209–2220 (2009).
pubmed: 19843557
doi: 10.1056/NEJMoa0908492
Hammer, S. M. et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 369, 2083–2092 (2013).
pubmed: 24099601
pmcid: 4030634
doi: 10.1056/NEJMoa1310566
Gray, G. E. et al. Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults. N. Engl. J. Med. 384, 1089–1100 (2021).
pubmed: 33761206
pmcid: 7888373
doi: 10.1056/NEJMoa2031499
A study to assess the efficacy of a heterologous prime/boost vaccine regimen of Ad26.Mos4.HIV and aluminum phosphate-adjuvanted clade C gp140 in preventing human immunodeficiency virus (HIV)-1 infection in women in Sub-Saharan Africa. NIH https://ClinicalTrials.gov/show/NCT03060629 (2022).
A study of heterologous vaccine regimen of adenovirus serotype 26 Mosaic4 human immunodeficiency virus (Ad26.Mos4.HIV), adjuvanted clade C gp140 and Mosaic gp140 to prevent HIV-1 infection among cis-gender men and transgender individuals who have sex with cis-gender men and/or transgender individuals. NIH https://ClinicalTrials.gov/show/NCT03964415 (2023).
Vaccari, M. et al. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat. Med. 22, 762–770 (2016).
pubmed: 27239761
pmcid: 5916782
doi: 10.1038/nm.4105
Vaccari, M. et al. HIV vaccine candidate activation of hypoxia and the inflammasome in CD14
pubmed: 29785023
pmcid: 5992093
doi: 10.1038/s41591-018-0025-7
Bissa, M. et al. HIV vaccine candidate efficacy in female macaques mediated by cAMP-dependent efferocytosis and V2-specific ADCC. Nat. Commun. 14, 575 (2023).
pubmed: 36732510
pmcid: 9894672
doi: 10.1038/s41467-023-36109-8
Silva de Castro, I. et al. Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. iScience 24, 102047 (2021).
pubmed: 33554060
pmcid: 7847973
doi: 10.1016/j.isci.2021.102047
Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275–1286 (2012).
pubmed: 22475592
pmcid: 3371689
doi: 10.1056/NEJMoa1113425
Goes, L. R. et al. The V2 loop of HIV gp120 delivers costimulatory signals to CD4
pubmed: 33288704
pmcid: 7768698
doi: 10.1073/pnas.2011501117
Gschwandtner, M., Derler, R. & Midwood, K. S. More than just attractive: how CCL2 influences myeloid cell behavior beyond chemotaxis. Front. Immunol. 10, 2759 (2019).
pubmed: 31921102
pmcid: 6923224
doi: 10.3389/fimmu.2019.02759
Tomalka, J. A. et al. The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. Nat. Immunol. 22, 1294–1305 (2021).
pubmed: 34556879
pmcid: 8525330
doi: 10.1038/s41590-021-01026-9
Negreiros-Lima, G. L. et al. Cyclic AMP regulates key features of macrophages via PKA: recruitment, reprogramming and efferocytosis. Cells 9, 128 (2020).
pubmed: 31935860
pmcid: 7017228
doi: 10.3390/cells9010128
Doran, A. C., Yurdagul, A. Jr. & Tabas, I. Efferocytosis in health and disease. Nat. Rev. Immunol. 20, 254–267 (2020).
pubmed: 31822793
doi: 10.1038/s41577-019-0240-6
Rahman, M. A. et al. Differential effect of mucosal NKp44
pubmed: 31554692
doi: 10.4049/jimmunol.1900572
Turpin, J. A., Schito, M. L., Jenkins, L. M., Inman, J. K. & Appella, E. Topical microbicides: a promising approach for controlling the AIDS pandemic via retroviral zinc finger inhibitors. Adv. Pharm. 56, 229–256 (2008).
doi: 10.1016/S1054-3589(07)56008-4
Jenkins, L. M. et al. Studies on the mechanism of inactivation of the HIV-1 nucleocapsid protein NCp7 with 2-mercaptobenzamide thioesters. J. Med. Chem. 48, 2847–2858 (2005).
pubmed: 15828823
doi: 10.1021/jm0492195
Turpin, J. A. et al. Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles. J. Virol. 70, 6180–6189 (1996).
pubmed: 8709244
pmcid: 190642
doi: 10.1128/jvi.70.9.6180-6189.1996
Miller Jenkins, L. M. et al. Small-molecule inactivation of HIV-1 NCp7 by repetitive intracellular acyl transfer. Nat. Chem. Biol. 6, 887–889 (2010).
pubmed: 20953192
doi: 10.1038/nchembio.456
Wallace, G. S. et al. Human immunodeficiency virus type 1 nucleocapsid inhibitors impede trans infection in cellular and explant models and protect nonhuman primates from infection. J. Virol. 83, 9175–9182 (2009).
pubmed: 19587055
pmcid: 2738238
doi: 10.1128/JVI.00820-09
Schito, M. L. et al. In vivo antiviral activity of novel human immunodeficiency virus type 1 nucleocapsid p7 zinc finger inhibitors in a transgenic murine model. AIDS Res. Hum. Retroviruses 19, 91–101 (2003).
pubmed: 12639244
doi: 10.1089/088922203762688595
Cheng-Mayer, C. et al. Delay of simian human immunodeficiency virus infection and control of viral replication in vaccinated macaques challenged in the presence of a topical microbicide. AIDS 25, 1833–1841 (2011).
pubmed: 21750420
doi: 10.1097/QAD.0b013e32834a1d94
Helmold Hait, S. et al. An SAMT-247 microbicide provides potent protection against intravaginal simian immunodeficiency virus infection of rhesus macaques, whereas an added vaccine component elicits mixed outcomes. J. Immunol. 204, 3315–3328 (2020).
pubmed: 32393514
doi: 10.4049/jimmunol.2000165
Henson, P. M. Cell removal: efferocytosis. Annu. Rev. Cell Dev. Biol. 33, 127–144 (2017).
pubmed: 28613937
doi: 10.1146/annurev-cellbio-111315-125315
Cicala, C. et al. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc. Natl Acad. Sci. USA 106, 20877–20882 (2009).
pubmed: 19933330
pmcid: 2780317
doi: 10.1073/pnas.0911796106
Kader, M., Bixler, S., Roederer, M., Veazey, R. & Mattapallil, J. J. CD4 T cell subsets in the mucosa are CD28+Ki-67−HLA−DR−CD69+ but show differential infection based on alpha4beta7 receptor expression during acute SIV infection. J. Med. Primatol. 38, 24–31 (2009).
pubmed: 19863675
pmcid: 2813512
doi: 10.1111/j.1600-0684.2009.00372.x
Redmond, W. L., Ruby, C. E. & Weinberg, A. D. The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit. Rev. Immunol. 29, 187–201 (2009).
pubmed: 19538134
pmcid: 3180959
doi: 10.1615/CritRevImmunol.v29.i3.10
Blair, P. J. et al. CD40 ligand (CD154) triggers a short-term CD4
pubmed: 10684857
pmcid: 2195831
doi: 10.1084/jem.191.4.651
Cibrian, D. & Sanchez-Madrid, F. CD69: from activation marker to metabolic gatekeeper. Eur. J. Immunol. 47, 946–953 (2017).
pubmed: 28475283
pmcid: 6485631
doi: 10.1002/eji.201646837
Soares, A. et al. Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation. J. Immunol. Methods 362, 43–50 (2010).
pubmed: 20800066
pmcid: 2989440
doi: 10.1016/j.jim.2010.08.007
Parry, R. V. et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25, 9543–9553 (2005).
pubmed: 16227604
pmcid: 1265804
doi: 10.1128/MCB.25.21.9543-9553.2005
Blank, C. & Mackensen, A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol. Immunother. 56, 739–745 (2007).
pubmed: 17195077
doi: 10.1007/s00262-006-0272-1
Tian, X. et al. The upregulation of LAG-3 on T cells defines a subpopulation with functional exhaustion and correlates with disease progression in HIV-infected subjects. J. Immunol. 194, 3873–3882 (2015).
pubmed: 25780040
doi: 10.4049/jimmunol.1402176
Read, S. A., Obeid, S., Ahlenstiel, C. & Ahlenstiel, G. The role of zinc in antiviral immunity. Adv. Nutr. 10, 696–710 (2019).
pubmed: 31305906
pmcid: 6628855
doi: 10.1093/advances/nmz013
Prasad, A. S., Miale, A. Jr., Farid, Z., Sandstead, H. H. & Schulert, A. R. Zinc metabolism in patients with the syndrome of iron deficiency anemia, hepatosplenomegaly, dwarfism, and hypognadism. J. Lab. Clin. Med. 61, 537–549 (1963).
pubmed: 13985937
Tone, K., Suzuki, T. & Todoroki, T. Influence of zinc deficiency on phagocytosis in mice. Kitasato Arch. Exp. Med 64, 263–269 (1991).
pubmed: 1823923
Wirth, J. J., Fraker, P. J. & Kierszenbaum, F. Zinc requirement for macrophage function: effect of zinc deficiency on uptake and killing of a protozoan parasite. Immunology 68, 114–119 (1989).
pubmed: 2680908
pmcid: 1385514
Hamon, R. et al. Zinc and zinc transporters in macrophages and their roles in efferocytosis in COPD. PLoS ONE 9, e110056 (2014).
pubmed: 25350745
pmcid: 4211649
doi: 10.1371/journal.pone.0110056
Haase, H. et al. Zinc signals are essential for lipopolysaccharide-induced signal transduction in monocytes. J. Immunol. 181, 6491–6502 (2008).
pubmed: 18941240
doi: 10.4049/jimmunol.181.9.6491
Jenkins, J. L. & Urban, L. Phenotypic screening: fishing for neuroactive compounds. Nat. Chem. Biol. 6, 172–173 (2010).
pubmed: 20154663
doi: 10.1038/nchembio.320
Miller Jenkins, L. M. et al. Inhibition of HIV maturation via selective unfolding and cross-linking of Gag polyprotein by a mercaptobenzamide acetylator. J. Am. Chem. Soc. 141, 8327–8338 (2019).
pubmed: 31042030
pmcid: 8496520
doi: 10.1021/jacs.9b02743
Lambert, S. A. et al. The human transcription factors. Cell 172, 650–665 (2018).
pubmed: 29425488
doi: 10.1016/j.cell.2018.01.029
Andreini, C. & Bertini, I. A bioinformatics view of zinc enzymes. J. Inorg. Biochem. 111, 150–156 (2012).
pubmed: 22209023
doi: 10.1016/j.jinorgbio.2011.11.020
Gammoh, N. Z. & Rink, L. Zinc in infection and inflammation. Nutrients 9, 624 (2017).
pubmed: 28629136
pmcid: 5490603
doi: 10.3390/nu9060624
Wessels, I., Maywald, M. & Rink, L. Zinc as a gatekeeper of immune function. Nutrients 9, 1286 (2017).
pubmed: 29186856
pmcid: 5748737
doi: 10.3390/nu9121286
Sheikh, A. et al. Zinc influences innate immune responses in children with enterotoxigenic Escherichia coli-induced diarrhea. J. Nutr. 140, 1049–1056 (2010).
pubmed: 20237063
doi: 10.3945/jn.109.111492
Kjellerup, L., Winther, A. L., Wilson, D. & Fuglsang, A. T. Cyclic AMP pathway activation and extracellular zinc induce rapid intracellular zinc mobilization in Candida albicans. Front. Microbiol. 9, 502 (2018).
pubmed: 29619016
pmcid: 5871664
doi: 10.3389/fmicb.2018.00502
Kido, T., Suka, M. & Yanagisawa, H. Effectiveness of interleukin-4 administration or zinc supplementation in improving zinc deficiency-associated thymic atrophy and fatty degeneration and in normalizing T cell maturation process. Immunology 165, 445–459 (2022).
pubmed: 35138640
doi: 10.1111/imm.13452
Orlandi, C., Flinko, R. & Lewis, G. K. A new cell line for high throughput HIV-specific antibody-dependent cellular cytotoxicity (ADCC) and cell-to-cell virus transmission studies. J. Immunol. Methods 433, 51–58 (2016).
pubmed: 26969387
pmcid: 4869150
doi: 10.1016/j.jim.2016.03.002
Reiss, S. et al. Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells. PLoS ONE 12, e0186998 (2017).
pubmed: 29065175
pmcid: 5655442
doi: 10.1371/journal.pone.0186998